39
Participants
Start Date
May 31, 2014
Primary Completion Date
February 28, 2017
Study Completion Date
February 28, 2017
Placebo treatment
Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Liraglutide treatment
Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital, Aalborg
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
Aalborg University Hospital
OTHER